Replies to post #129502 on Biotech Values

[genisi]

The burden of proof is on proving superiority. All they can say now if they are both superior to PBO. From a sales and marketing standpoint, that's a big difference.

Not necessarily so: Rebif showed superiority over Avonex in the EVIDENCE trial and yet Avonex remains the top-selling interferon.